Kadmon Holdings gets FDA OK for generic Syprine

Press enter to search
Close search
Open Menu

Kadmon Holdings gets FDA OK for generic Syprine

By Sandra Levy - 09/24/2019

Kadmon Holdings has received the Food and Drug Administration’s nod for trientine hydrochloride capsules in a dosage strength of 250 mg.

The product is the generic of Bausch Health’s Syprine capsules, 250 mg.

Trientine hydrochloride is used for the treatment of Wilson’s disease in patients who are intolerant of penicillamine. Wilson’s disease is a rare genetic disorder causing excess copper accumulation in the body and can cause severe hepatic, neurologic and psychiatric symptoms.

RELATED TOPICS